Advanced AI technology enables us to develop a special class of compound that’s designed to precisely target and treat diseases at the genetic level.
Unique drug design blocks pathogenic RNAs in multiple diseases, including cancer
Proprietary chemistry yields smaller, more specific, less toxic drugs
Targeted delivery agent carries modified RNA drugs into disease cells, reducing toxicity to normal cells
Bound Therapeutics is a pioneering biotechnology firm dedicated to the development of RNA-based therapies targeting rare and refractory diseases, with a primary focus on oncology. Our proprietary platform, Magic Bullet Designer (MBD), utilizes advanced artificial intelligence and machine learning algorithms to optimize the tissue-specific delivery of RNA therapeutics, thereby enhancing precision and therapeutic efficacy.
Currently in the preclinical stage, our pipeline encompasses novel treatments for aggressive malignancies and genetic disorders, positioning Bound Therapeutics at the forefront of next-generation RNA therapeutics.
Bound Therapeutics was founded in 2015 by a team of renowned scientists and biopharmaceutical leaders driven to revolutionize cancer treatment through innovative RNA therapeutics. Combining decades of expertise, the company developed a proprietary AI-optimized nanocomplex platform to overcome traditional pharmaceutical limitations and address unmet medical needs.
Bound Therapeutics Strives to Improve Lifespan and Quality of Life
Bound Therapeutics is led by a seasoned team of biotech veterans with deep expertise in AI-driven drug discovery, nanoparticle engineering, oncology research, and successful pharmaceutical commercialization.
Connect with us to learn more about our technology and explore partnership opportunities.
Bound Therapeutics
Cambridge Innovation Center (CIC)
3675 Market Street, Suite 200
Philadelphia, PA 19104
